Evidence map›Paper›PMID 24892262›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A Hanauer, Shuang Zhao, John M Magenau, Kathryn Schultz, Hemasri Tokala, James L M Ferrara and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.Hawai'i journal of health & social welfare · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Noninfectious complications of hematopoietic cell transplantation.Hematology. American Society of Hematology. Education Program · 2021
    Article
  17. Article
  18. Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Lawrence ChangDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
David FrameCollege of Pharmacy, University of Michigan, Ann Arbor, Michigan.
Thomas BraunDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Erin GatzaDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
David A HanauerDepartment of Pediatrics, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan; Informatics Core of the Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
Shuang ZhaoUniversity of Michigan Medical School, University of Michigan, Ann Arbor, Michigan.
John M MagenauDepartment of Internal Medicine, Division of Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
Kathryn SchultzDepartment of Pharmacy, Rush University Medical Center, Chicago, Illinois.
Hemasri TokalaDepartment of Internal Medicine, Michigan State University, East Lansing, Michigan.
James L M FerraraDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
John E LevineDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
Pavan ReddyDepartment of Internal Medicine, Division of Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
Sophie PaczesnyDepartment of Pediatric Hematology-Oncology, Indiana University, Indianapolis, Indiana.
Sung Won ChoiDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan. Electronic address: sungchoi@umich.edu.
University of Michigan–Ann Arbor · USIndiana University – Purdue University Indianapolis · USMichigan Center for Translational Pathology · USMichigan State University · USRush University Medical Center · US

Funding

TUMOR VACCINES AND BONE MARROW TRANSPLANTATIONP01CA039542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JAMES L. M. FERRARA · 1985 to 2026
$47.9M
Graft versus Host Disease Biomarkers: Prediction of Onset and Response to TherapyRC1HL101102 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PACZESNY, SOPHIE · 2009 to 2010
$1000k
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease InhibitorsR01CA174667 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI PACZESNY, SOPHIE, YANG, CHAO-YIE · 2013 to 2015
$975k
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHDK23AI091623 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHOI, SUNG WON · 2011 to 2015
$658k
NCI NIH HHS P01 CA039542NCI NIH HHS R01 CA174667NCI NIH HHS R01CA174667NHLBI NIH HHS RC1 HL101102NIAID NIH HHS 1K23AI091623NIAID NIH HHS K23 AI091623
6 · The paper itself

Abstract

Engraftment syndrome (ES), characterized by fever, rash, pulmonary edema, weight gain, liver and renal dysfunction, and/or encephalopathy, occurs at the time of neutrophil recovery after hematopoietic cell transplantation (HCT). In this study, we evaluated the incidence, clinical features, risk factors, and outcomes of ES in children and adults undergoing first-time allogeneic HCT. Among 927 patients, 119 (13%) developed ES at a median of 10 days (interquartile range 9 to 12) after HCT. ES patients experienced significantly higher cumulative incidence of grade 2 to 4 acute GVHD at day 100 (75% versus 34%, P < .001) and higher nonrelapse mortality at 2 years (38% versus 19%, P < .001) compared with non-ES patients, resulting in lower overall survival at 2 years (38% versus 54%, P < .001). There was no significant difference in relapse at 2 years (26% versus 31%, P = .772). Suppression of tumorigenicity 2, interleukin 2 receptor alpha, and tumor necrosis factor receptor 1 plasma biomarker levels were significantly elevated in ES patients. Our results illustrate the clinical significance and prognostic impact of ES on allogeneic HCT outcomes. Despite early recognition of the syndrome and prompt institution of corticosteroid therapy, outcomes in ES patients were uniformly poor. This study suggests the need for a prospective approach of collecting clinical features combined with correlative laboratory analyses to better characterize ES.

Indexed as

FemaleGraft SurvivalHematopoietic Stem Cell TransplantationHumansMalePrognosisRisk FactorsSyndromeTransplantation ConditioningTransplantation, HomologousTreatment OutcomeCytokine stormEngraftment syndromeHematopoietic cell transplantation

Identifiers

PMID24892262
PMCPMC4142041
OpenAlexW2075388288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.